ReviewFrontiers in immunology2026
Oncolytic viruses in head and neck cancer: therapeutic promise and translational challenges.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Head and neck squamous cell carcinoma (HNSCC) remains difficult to treat, particularly in patients with HPV-negative disease. These patients often get diagnosed too late, their cancer doesn't respond well to treatment, and they don't live as long. Oncolytic viruses (OVs) can be used for treating cancer instead of using other cytotoxic methods since they can kill malignant cells directly and cause both local and systemic anti-cancer immune responses. In this review, we focus on current evidence of oncolytic virotherapy (OVT) in HNSCC, including that OVs selectively infect tumor cells, induce tumor cell lysis and immunogenic cell death, and modulate the tumor microenvironment. We also compare some OV platforms which were studied in HNSCC or similar solid-tumor settings: Herpes simplex virus (HSV), adenovirus, vaccinia virus, reovirus, measles virus, vesicular stomatitis virus, and Newcastle disease virus. Finally, we discuss emerging strategies to improve the efficacy and clinical translation of OVT for HNSCC, including tumor- or stimulus-responsive promoters, engineering of viral tropism and receptor specificity, modulation of both antiviral and immunosuppressive pathways, and incorporation between therapeutic payloads and advanced delivery systems. Altogether these developments support further exploration of OVs within biomarker-informed multimodal therapy for select patients of HNSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.